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Telomeres are the protective structure at both ends of each chromo- The decelerating age-adjusted LTL attrition in cancer cases as they
some. Telomere length is widely considered a marker of biological
aging. For convenience, telomere lengths in human population studies
have been predominately measured in peripheral blood leukocytes. Al-
though leukocyte telomere length (LTL) is generally inversely correlat-
ed with age, there is considerable inter-individual variation of LTL
among people of the same ages (Aubert and Lansdorp, 2008). An
individual's LTL at any given age is determined by a combination of ge-
netic, environmental, and lifestyle factors (Lin et al., 2012). The inter-
individual variation of LTL has been proposed to contribute to an
individual's susceptibility to age-related diseases, including cancer.
Since the ﬁrst epidemiologic study linking short LTL with increase
risks of several cancers in 2003 (Wu et al., 2003), there have been nu-
merous studies assessing the association of LTL with the risks of cancer
(Weischer et al., 2013;Wentzensen et al., 2011), but the resultswere in-
consistent. The inconsistent results are often attributed to technical var-
iations in LTL measurement methods, “reverse causation” limitation in
retrospective case control studies, small sample size of cancer cases in
prospective cohort studies, and heterogeneous populations. Further-
more, all the published studies relating LTL to cancer risks have used a
single time measurement of LTL without consideration of longitudinal
changes of LTL. In this issue of EBioMedicine, Hou et al. (2015), for the
ﬁrst time, reported a dynamic change of LTL in the context of cancer
risks. This study included 792 Normative Aging Study participants
with one to four LTL measurements during a follow-up of 12-years.
The authors observed that age-related LTL attrition was accelerated
among participants who ultimately developed cancer. Strikingly, this
trend reversed when age-adjusted LTL was examined relative to time
to diagnosis. This divergence of age-adjusted LTL attrition began seven
years pre-diagnosis and culminated in signiﬁcantly longer LTL 3–
4 years pre-diagnosis among cancer cases compared to cancer-free par-
ticipants, resulting in a positive association between longer LTL mea-
sured within 4 years of diagnosis and increased risks of prostate
cancer and all cancers combined. This provocative observation provides
important biological insight into the role of the telomeres in cancer eti-
ology and adds another possible explanation to the prior inconsistencies
in reporting the association of LTL with cancer risks.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.04.008.
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may be activated in the blood due to cancer initiation. Telomere integri-
ty is primarily maintained by telomerase, which catalyzes the synthesis
of telomere repeats and adds telomere sequences onto chromosome
ends. It is well known that telomere shortening is an early event in car-
cinogenesis. Critically shortened telomeres may trigger cellular senes-
cence and apoptosis. Activation of telomerase occurs in the majority of
cancers to counter-balance the critical shortening of telomeres in
tumor cells, which can stabilize and elongate telomeres, overcome se-
nescence and apoptosis, and increase cellular lifespan of malignant
cells. Prior studies have also reported telomerase activity in normal
and leukocytes (Broccoli et al., 1995). Biologically, it is fathomable that
individuals with higher telomere erosion rate over their early lifetime
have increased cancer risks; however, as their LTL reaches a threshold
and cancer is well on its trajectory of development, their telomere elon-
gation mechanisms are hijacked to stabilize and elongate telomeres
even in blood leukocytes, thus, providing better survival. Normal leuko-
cytes beneﬁt from telomere elongationmechanisms, resulting in longer
LTL for cancer patients near their diagnosis.
This divergence of LTL at some point before cancer diagnosis has im-
portant implications in assessing the relationship of LTL with the cancer
risks. Current literature in this regard all measured LTL at a single time
point. The timing of blood collection was not strictly controlled. The
above observation by Hou et al. (2015) indicates that the differences
in sample collection time relative to cancer development and diagnosis
will have a signiﬁcant impact on assessing the association of LTL with
cancer risks, which at least partially contributes to the inconsistency in
literature. Future association studies of single time measurement of
LTL should carefully control the timing of blood collection. More impor-
tantly, studies withmultiple blood collection are warranted to establish
the temporal associations between LTL and cancer risks, and to assess
the dynamic changes of LTL in relation to cancer development.
Due to the small sample size, this study of Hou et al. (2015) could
only evaluate prostate cancer and the odds ratio is likely inﬂated.
Whether a similar phenomenon occurs to other cancer types is unclear.
Recent large cross-sectional studies and prospective studies have
shown that both long LTL and short LTL can predispose individuals to in-
creased cancer risks and the direction of association is not only cancer
type-dependent, but also histology-dependent (Weischer et al., 2013;
Gu and Wu, 2013; Sanchez-Espiridion et al., 2014; Seow et al., 2014).
For example, long LTL was associated with an increased risk of lung ad-
enocarcinoma, whereas short LTL was associated with a reduced risk ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
494 J. Gu / EBioMedicine 2 (2015) 493–494lung squamous cell carcinoma (Sanchez-Espiridion et al., 2014; Seow
et al., 2014). The study of Hou et al. (2015) adds additional complexity
to the link of LTL to cancer risks. The cancer type- and histology-
dependent association between LTL and cancer risks, accelerated age-
related LTL shortening in cancer cases, and decelerating age-adjusted
LTL attrition in cancer cases as they approach diagnosis, all point to
a complex and dynamic relationship between LTL and cancer develop-
ment. Future large, prospective, longitudinal studies are needed to con-
ﬁrm and extend the intriguing observations of Hou et al. (2015). A full
understanding of LTL epidemiology and cancer associationwill facilitate
intervention efforts to prevent cancer and improve our lives through
modulating telomere dynamics.
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